PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer
出版年份 2015 全文链接
标题
PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer
作者
关键词
-
出版物
Scientific Reports
Volume 5, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-09-11
DOI
10.1038/srep14035
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy Cetuximab in Cervical Cancer Patients
- (2015) A. de la Rochefordiere et al. CLINICAL CANCER RESEARCH
- Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience
- (2015) Ming-Mo Hou et al. Oncotarget
- Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo
- (2014) Salvatore Lopez et al. GYNECOLOGIC ONCOLOGY
- A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer
- (2014) Domenica Lorusso et al. GYNECOLOGIC ONCOLOGY
- Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
- (2014) Ingrid A. Mayer et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study
- (2014) Vicky S. Sabine et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- Oncogenic mutations in cervical cancer
- (2013) Alexi A. Wright et al. CANCER
- Landscape of genomic alterations in cervical carcinomas
- (2013) Akinyemi I. Ojesina et al. NATURE
- PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
- (2012) F. Janku et al. CANCER RESEARCH
- Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
- (2012) J. M. Spoerke et al. CLINICAL CANCER RESEARCH
- PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy
- (2012) John B. McIntyre et al. GYNECOLOGIC ONCOLOGY
- PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations
- (2012) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas
- (2011) Meghan L. Rudd et al. CLINICAL CANCER RESEARCH
- PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
- (2011) Filip Janku et al. PLoS One
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences
- (2008) Takahito Miyake et al. CANCER LETTERS
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now